RE: From the other board this puts things into perspective7 Oct 2020 22:26
Hi Qd22,
Indeed I went through the ppt earlier. It’s actually not the Blautix results that are a problem it’s the placebo results and the delta. That differentiation is not statistically significant. Hence more work to break down the sub groups. Age, gender, types of IBS = smaller sub group. Some individual results are better, so need a bigger study but imo it’s the results across cohorts that have spooked the market. That spook = more time, another trial, don’t know for sure..yet.
It has the potential for amazing things...
So you can stick around or take profits and come back. Even if one pays more than 109 the ‘surety’ of what’s next may be worth it. In the meantime one could make good money from elsewhere, AVCT, ONC or others. It’s just the realities of AIM
Usual caveats
Trek